Growing research points to the Mediterranean diet as a potential modulator of inflammation, beta-amyloid deposition, and other pathways central to Alzheimer progression.

The Supplemental Nutrition Assistance Program plays a role in slowing cognitive decline by alleviating food insecurity, but challenges related to accessibility and systemic inequities continue to restrict the program’s ability to support healthy aging.

An 80-year-old woman is admitted from the emergency department to the telemetry floor after feeling disoriented and confused. At approximately 10 PM, the patient was noted to be restless. She began to get out of her bed. After being returned to her bed several times, the patient was given a sedative and diagnosed with sundowning.

Nonmodifiable risk factors for DLB include age and family history. Risk increases substantially in individuals with a first-degree relative who has DLB, including a 2-fold increase if a sibling is affected.

Primary care providers have the potential to help prevent their patients with AF from developing all-cause dementia by managing their treatment effectively. Taking a few moments to review a patient’s medications and assess their mental status could significantly extend their lifespan and enhance their overall quality of life.

Dylan Wint, MD, highlights key barriers in Alzheimer disease care and emphasizes a multidisciplinary approach to improve quality of life for both patients and caregivers.

Dementia risk has been linked to air pollution exposure — particularly PM2.5 exposure — through a growing body of medical research.

The Alzheimer’s Association released a new clinical practice guideline for clinicians in primary and specialty care on how to diagnose patients with suspected Alzheimer disease (AD) and AD-related dementias.

Drs Bruneau, Tang, and Hofman discuss barriers to health care faced by patients with Alzheimer disease (AD), as well as intervention methods that may help address health disparities in AD.

We’ve developed a comprehensive patient fact sheet on the defining symptoms of delirium and dementia and ways in which the 2 disease states can be differentially diagnosed.

Neurology Advisor explored the controversial approval process of aducanumab for Alzheimer disease and the effects it had on public trust in the US Food and Drug Administration.

Dr Paulson, a neurology professor and director of the Alzheimer Center at the University of Michigan Medical School, provides insights into frontotemporal dementia and aphasia.

Clinical trial investigators explore the headway made by diversity, equity, and inclusion initiatives in clinical trials of Alzheimer disease and related dementias and the challenges that still persist.

Researchers from WashU, NAPA, and the Alzheimer’s Association presented updates on advancements in Alzheimer disease treatments, research, and care.

Exercise is likely to slow the onset and progression of brain changes and dementia due to Alzheimer disease.

Estrogen hormone therapy begun near the onset of menopause can decrease all-cause mortality and possibly prevent age-related cognitive decline in women.

Blood tests for Alzheimer disease may improve diagnostic accuracy and treatment options.

In an expert roundtable, clinicians discuss the risks, benefits, and anticipated real-world usage of lecanemab following US FDA approval.

These are the clinical trials that led to the FDA’s approval of aducanumab and lecanemab for early AD, plus, the concerns that loom.

Mehdi Jorfi, PhD, discusses the opportunities to optimize the development and application of neurotechnologies for AD.

Timothy S. Chang, MD, PhD and Lisa L. Barnes, PhD, discuss health disparities in ADRD and how to improve clinical outcomes for patients from underrepresented groups.

Joseph D. Dougherty, PhD discusses genetic compounds’ ability to clear amyloid-β from the brain in patients with Alzheimer disease.

Aduhelm, a monoclonal antibody that targets amyloid-beta, is covered under Medicare for beneficiaries enrolled in clinical trials.

We spoke with Rebecca Edelmayer, PhD, the Alzheimer’s Association Senior Director of Scientific Engagement, about studies presented at the Alzheimer’s Association International Conference (AAIC) 2022 regarding individual’s life experiences and brain health.

Ines Moreno-Gonzalez, PhD, an adjunct associate professor of neurology, explains healthy aging can help reduce lifestyle risk factors for Alzheimer disease.

Geriatric specialists discuss the long-term physical, mental, and social effects of the COVID-19 pandemic on people living with dementia and their caregivers.

Jiu-Chiuan Chen, MD, ScD and Diana Younan, PhD, MPH discuss the importance of understanding the relationship between air pollution and dementia risk and how clinicians can help patients mitigate their risk.

The link between head injury and dementia risk is not straightforward, but a neurologist and neuropsychologist discuss potential mechanisms and prevention efforts that can help increase awareness and minimize cognitive problems.

An overview on the role of alcohol use in dementia, using findings from various studies and expert commentary from Cynthia A. Munro, PhD, ABBP(CN).

Tracy Butler, MD, discusses the potential of leuprolide acetate for the treatment of Alzheimer disease in women also receiving the acetylcholinesterase inhibitor donepezil.